Executive Sponsors

VirtualScopics, Inc.

Associate Sponsors

Cancer Genetics
HTG Molecular
Neon Therapeutics

Supporting Sponsors

Defined health


BioMedical Systems
Biotech Corporation
Loncar Investments
Provecs Medical
World Courier

Supporting Partners

Cancer Research Institute

Media Partners

Advances in Modern Oncology Research, AMOR
BioPharm Clinical
BioPharma Dive
Clinical Leader
K BioSciences
Medical News Today
Pharma VOICE
Technology Networks

IO 360 Supports

Dance Against Cancer
Emily Whitehead Foundation


The Conference Forum would like to thank everyone involved with the 2nd annual Immuno-Oncology 360° event.

We want to thank our IO supporting partners and sponsors for their insights and support on content and agenda development. In particular, we would like to thank our lead advisors, Dr Axel Hoos (GSK) and Dr James Gulley (NCI), for their unwavering guidance, expertise and enthusiasm to present a unique 360-degree program for cancer immunotherapy.


​IO360 Co-chairs Dr. Axel Hoos, GSK and Dr. James Gulley, NCI


​Dr. Jedd Wolchok, MSCKK and Kate Woda, The Conference Forum


​Dr. Carl June, University of Pennsylvania delivers Keynote at IO360












With rapid development of cancer immunotherapy drug development, breakthrough FDA approval status, and fast-tracking clinical trials, competition is fierce. The science behind immune-based therapies is driving rapid change. Both small and large companies are racing to bring game-changing therapies to the market and in many cases, partnering to maximize on combination therapies. As a result, innovative approaches and developments are also creating increased momentum for investment/business development opportunities.


​Left to Right: Dr. Carl June, UPenn, Kate Woda and Valerie Bowling, The Conference Forum, Dr. James Gulley, NCI and Dr. Axel Hoos, GSK


The 2nd annual Immuno-Oncology 360° event delved into key areas of business, clinical and scientific advancements including:

  • Business Aspects for IO
  • Differences of Modalities in Immunotherapy
  • Methodological Advances – Investigating Immunotherapies in the Clinic
  • Immunotherapy Practice Altering Clinical Advances
  • Hematologic Malignancies
  • Emerging Biomarkers
  • Randomized Phase II Combination Therapy Trials

IO360° Videos

Save the date for the 3rd Annual Immuno-Oncology 360° program scheduled to take place February 2-3, 2017 in NYC.


Kate Woda B&W


Kate Woda
Conference Director


Valerie Bowling New


Valerie Bowling
Executive Director


Jessica Rothenberg B&W


Jessica Rothenberg
Marketing Director


Meredith Sands B&W


Meredith Sands
Executive Director, Business Development


Elizabeth Bard B&W


Elizabeth Bard
Business Development Manager




Geeta Bachani
Business Development Manager


Bridget Murphy B&W


Bridget Murphy
Conference Logistic Planner